Last reviewed 2026-04-19 · How we verify

Bacterial pneumonia

Approved treatments

• Ramycin
  Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins.
• Doxycyclin · Bulovka Hospital
• Garamycin · Merck & Co.
• Eryped · Arbor Pharms Llc
• Amoxycillin · King George's Medical University
• Ancef In Sodium Chloride 0.9% In Plastic Container · GSK
• Ancef In Sodium Chloride 0.9% In Plastic Container · GSK
  Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis.
• Nuzyra · Paratek Pharms
  Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
• Maxipime · Baxter
  Cefepime is a cephalosporin antibacterial drug.
• Claforan · Sterimax
• Unasyn · Bristol-Myers Squibb
• Avelox · Bayer AG
  Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms.
• Factive · Lg Chem Ltd
• Nuzyra · Paratek Pharms
  Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
• Factive · Lg Chem Ltd
• Ceftin · GSK
  Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death.
• Maxipime · Baxter
  Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis.
• Pipracil
  Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death.
• Amoxil · Generic (originally Beecham/GSK)
  Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins.
• E-Mycin · Generic (originally Abbott/Lilly)
• Cefepim · University Hospital Tuebingen
• Ciprofloxacine · Poitiers University Hospital
• Gentamicin · Merck & Co.
• Avelox · Novartis Pharmaceuticals
• Geninax
• Ceftriaxon · Centre Hospitalier Universitaire Vaudois
• Xenleta · Hong Kong
• Zithromax · Pfizer Inc.
  Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life.
• Zymar · Allergan
• Invanz · Merck & Co.
  Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Primaxin · Merck Sharp & Dohme B.V.
  Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Arikayce Kit · Bristol-Myers Squibb
  Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.
• Fortaz · Pai Holdings Pharm
  Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death.
• Mefoxin In Sodium Chloride 0.9% In Plastic Container
• Benzamycin · Pfizer
• Vantin
• Cefotan
• Primaxin · Merck & Co.
  Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body.
• Vibativ · Cumberland
  Vibativ works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.
• TICARCILLIN
• Ticarcillin
• Zinacef · GSK
  Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Kanacin · Bristol-Myers Squibb
• Augmentin 250 · Dr Reddys Labs Inc
• Fortaz · Pai Holdings Pharm
  Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance.
• Cefditoren Pivoxyl · Vansen Pharma
• Zosyn · Merck Sharp & Dohme B.V.
  Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively.
• Noroxin
• Floxin
• Cipro · Bayer AG

Clinical guidelines

• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of genital infections.
• FDA label — 1L
  Ceftazidime is indicated for the treatment of lower respiratory tract infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp., Haemophilus influenzae, including ampicillin-resistant strains, Klebsiella spp., Enterobacter spp., Proteus mirabilis, Escherichia coli, Serratia spp., Citrobacter spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).
• FDA label — 1L
  Ceftazidime is indicated for the treatment of lower respiratory tract infections, including pneumonia, caused by Citrobacter spp.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of biliary infections due to Escherichia coli, various isolates of streptococci, Proteus mirabilis, and Staphylococcus aureus.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of urinary tract infections due to Escherichia coli and Proteus mirabilis.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus agalactiae.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of respiratory tract infections due to Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of biliary infections due to Escherichia coli, various isolates of streptococci, Proteus mirabilis, and Staphylococcus aureus.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of bone and joint infections.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of bone and joint infections.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of septicemia.
• FDA label — 1L
  Cefazolin for Injection and Dextrose Injection is indicated for the treatment of endocarditis.
• FDA label — 1L
  Cefepime for Injection and Dextrose Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.
• FDA label — 1L
  Cefepime for Injection and Dextrose Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
• FDA label — 1L
  Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.
• FDA label — 1L
  Cefepime for Injection and Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Bacterial pneumonia patent landscape — cliff calendar, originator estates, attackable patents
• Bacterial pneumonia treatment landscape brief
• Bacterial pneumonia treatment updates RSS

Frequently asked questions about Bacterial pneumonia

Related

• Treatment landscape: Bacterial pneumonia patent cliff · Bacterial pneumonia CI report
• Treatment: Ramycin
• Treatment: Doxycyclin · Bulovka Hospital
• Treatment: Garamycin · Merck & Co.
• Treatment: Eryped · Arbor Pharms Llc
• Treatment: Amoxycillin · King George's Medical University
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing